JP7749169B2 - 中枢神経系障害を処置するための組成物および方法 - Google Patents

中枢神経系障害を処置するための組成物および方法

Info

Publication number
JP7749169B2
JP7749169B2 JP2021572548A JP2021572548A JP7749169B2 JP 7749169 B2 JP7749169 B2 JP 7749169B2 JP 2021572548 A JP2021572548 A JP 2021572548A JP 2021572548 A JP2021572548 A JP 2021572548A JP 7749169 B2 JP7749169 B2 JP 7749169B2
Authority
JP
Japan
Prior art keywords
suramin
pharmaceutical composition
composition
less
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535920A (ja
JP2022535920A5 (cg-RX-API-DMAC7.html
Inventor
ホック セン タン,
マイケル ダービー,
ザッカリー ローム,
Original Assignee
クヴァトリス セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クヴァトリス セラピューティクス, インコーポレイテッド filed Critical クヴァトリス セラピューティクス, インコーポレイテッド
Publication of JP2022535920A publication Critical patent/JP2022535920A/ja
Publication of JP2022535920A5 publication Critical patent/JP2022535920A5/ja
Application granted granted Critical
Publication of JP7749169B2 publication Critical patent/JP7749169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021572548A 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法 Active JP7749169B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
US62/858,621 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (3)

Publication Number Publication Date
JP2022535920A JP2022535920A (ja) 2022-08-10
JP2022535920A5 JP2022535920A5 (cg-RX-API-DMAC7.html) 2023-05-23
JP7749169B2 true JP7749169B2 (ja) 2025-10-06

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572548A Active JP7749169B2 (ja) 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20220226268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3979985A4 (cg-RX-API-DMAC7.html)
JP (1) JP7749169B2 (cg-RX-API-DMAC7.html)
CN (1) CN114340597B (cg-RX-API-DMAC7.html)
AU (1) AU2020288999A1 (cg-RX-API-DMAC7.html)
CA (1) CA3142842A1 (cg-RX-API-DMAC7.html)
IL (1) IL288655A (cg-RX-API-DMAC7.html)
WO (1) WO2020247127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021319064A1 (en) * 2020-07-29 2023-03-23 Perfect Daylight Limited Methods of manufacture of suramin
US20230390223A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Administration of antipurinergic compositions for treating nervous system disorders
EP4229035A4 (en) * 2020-10-22 2024-07-31 Paxmedica, Inc. INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES
JP2024532288A (ja) * 2021-08-23 2024-09-05 パックスメディカ, インコーポレイテッド 抗プリン作動薬を用いて神経系障害を処置するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529916A (ja) 2014-09-02 2017-10-12 トゥール・フランソワ=ラブレー大学 流体製品の鼻腔スプレー装置
WO2018148262A1 (en) 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
JP2003506458A (ja) * 1999-08-11 2003-02-18 ジョセフ ピサ, シクロデキストリン誘導体の包接複合体形成の増強
JP2005519075A (ja) * 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
HRP20250215T1 (hr) * 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529916A (ja) 2014-09-02 2017-10-12 トゥール・フランソワ=ラブレー大学 流体製品の鼻腔スプレー装置
WO2018148262A1 (en) 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GHADIRI, M. et al.,Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes,Pharmaceutics,2019年03月,11(3):113,<DOI: 10.3390/pharmaceutics11030113>

Also Published As

Publication number Publication date
US20220226268A1 (en) 2022-07-21
EP3979985A4 (en) 2023-05-03
CA3142842A1 (en) 2020-12-10
IL288655A (en) 2022-02-01
JP2022535920A (ja) 2022-08-10
WO2020247127A1 (en) 2020-12-10
EP3979985A1 (en) 2022-04-13
AU2020288999A1 (en) 2022-02-03
CN114340597B (zh) 2025-01-28
CN114340597A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
CN114340597B (zh) 用于治疗中枢神经系统障碍的组合物和方法
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
ES2784843T3 (es) Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US9572825B2 (en) Compositions and methods for treating huntington&#39;s disease
JP2015145430A (ja) 薬剤の経口による生物学的利用能を向上させる方法及びより毒性の少ないオロチン酸塩組成物
US20160120865A1 (en) Topical treatment of localized scleroderma
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
US20230390226A1 (en) Intranasal administration of suramin for treating nervous system disorders
CZ2003966A3 (cs) Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
HK40073161B (en) Compositions and methods for treating central nervous system disorders
HK40073161A (en) Compositions and methods for treating central nervous system disorders
JP2019536769A (ja) 粘膜活性剤送達
EP4479048B1 (en) Bilastine composition for once-daily parenteral administration
IL227742A (en) Plumzanil complexes, compounds containing them and their uses

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250815

R150 Certificate of patent or registration of utility model

Ref document number: 7749169

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150